Literature DB >> 19453366

Intra-operative cisplatin for the treatment of canine extremity soft tissue sarcomas.

M Havlicek1, R S Straw, V Langova, W S Dernell.   

Abstract

Nineteen dogs with histologically confirmed soft tissue sarcomas of the extremities were treated with a combination of marginal surgery and intra-operative chemotherapy in the form of cisplatin in a biodegradable implant delivery system (Atrigel; Atrix Laboratories, Fort Collins, Co, USA). None of the dogs had evidence of metastasis at time of treatment. The median dose of cisplatin was 52.1 mg/m(2) (mean 55.4 mg/m(2), range 18.5-108.6 mg/m(2)). Wound complications were noted in 16 dogs (84.2%). Median follow-up time was 874 days (mean 777 days, range 125-1463 days). Nine dogs (47.3%) were alive at the time of analysis. Local recurrence occurred in three dogs (16.6%). The time to recurrence was 214, 264 and 874 days.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453366     DOI: 10.1111/j.1476-5829.2009.00182.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  2 in total

1.  Effects of intratumoral administration of a hyaluronan-cisplatin nanoconjugate to five dogs with soft tissue sarcomas.

Authors:  Rachel O Venable; Deanna R Worley; Daniel L Gustafson; Ryan J Hansen; E J Ehrhart; Shuang Cai; Mark S Cohen; M Laird Forrest
Journal:  Am J Vet Res       Date:  2012-12       Impact factor: 1.156

2.  The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study.

Authors:  Annika N Haagsman; Astrid C S Witkamp; Bart E Sjollema; Marja J L Kik; Jolle Kirpensteijn
Journal:  BMC Vet Res       Date:  2013-08-08       Impact factor: 2.741

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.